These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 9132622)

  • 21. Single i.v. ketamine augmentation of newly initiated escitalopram for major depression: results from a randomized, placebo-controlled 4-week study.
    Hu YD; Xiang YT; Fang JX; Zu S; Sha S; Shi H; Ungvari GS; Correll CU; Chiu HF; Xue Y; Tian TF; Wu AS; Ma X; Wang G
    Psychol Med; 2016 Feb; 46(3):623-35. PubMed ID: 26478208
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Declaration of treatment failures.
    Nierenberg AA; Mulroy R
    Mod Probl Pharmacopsychiatry; 1997; 25():17-33. PubMed ID: 9344367
    [No Abstract]   [Full Text] [Related]  

  • 23. Eighteen months of drug treatment for depression: predicting relapse and recovery.
    Mulder RT; Frampton CM; Luty SE; Joyce PR
    J Affect Disord; 2009 Apr; 114(1-3):263-70. PubMed ID: 18805590
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term efficacy and safety of milnacipran compared to clomipramine in patients with major depression.
    Leinonen E; Lepola U; Koponen H; Mehtonen OP; Rimon R
    Acta Psychiatr Scand; 1997 Dec; 96(6):497-504. PubMed ID: 9421348
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inadequacy of antidepressant treatment for patients with major depression who are at risk for suicidal behavior.
    Oquendo MA; Malone KM; Ellis SP; Sackeim HA; Mann JJ
    Am J Psychiatry; 1999 Feb; 156(2):190-4. PubMed ID: 9989553
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebo-controlled clinical trial.
    Furey ML; Drevets WC
    Arch Gen Psychiatry; 2006 Oct; 63(10):1121-9. PubMed ID: 17015814
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lithium carbonate versus cognitive therapy as sequential combination treatment strategies in partial responders to antidepressant medication: an exploratory trial.
    Kennedy SH; Segal ZV; Cohen NL; Levitan RD; Gemar M; Bagby RM
    J Clin Psychiatry; 2003 Apr; 64(4):439-44. PubMed ID: 12716247
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predictors of early recovery from major depression among persons admitted to community-based clinics: an observational study.
    Meyers BS; Sirey JA; Bruce M; Hamilton M; Raue P; Friedman SJ; Rickey C; Kakuma T; Carroll MK; Kiosses D; Alexopoulos G
    Arch Gen Psychiatry; 2002 Aug; 59(8):729-35. PubMed ID: 12150649
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A comparison of placebo responders and nonresponders in subgroups of depressive disorder.
    Bialik RJ; Ravindran AV; Bakish D; Lapierre YD
    J Psychiatry Neurosci; 1995 Jul; 20(4):265-70. PubMed ID: 7647079
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Major Depression Rating Scale (MDS). Inter-rater reliability and validity across different settings in randomized moclobemide trials. Danish University Antidepressant Group.
    Bech P; Stage KB; Nair NP; Larsen JK; Kragh-Sørensen P; Gjerris A
    J Affect Disord; 1997 Jan; 42(1):39-48. PubMed ID: 9089057
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Amitriptyline in combination with repeated late sleep deprivation versus amitriptyline alone in major depression. A randomised study.
    Kuhs H; Färber D; Borgstädt S; Mrosek S; Tölle R
    J Affect Disord; 1996 Feb; 37(1):31-41. PubMed ID: 8682976
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prediction of efficacy of antidepressant by 1-week test therapy in depression.
    Nagayama H; Nagano K; Ikezaki A; Tashiro T
    J Affect Disord; 1991 Dec; 23(4):213-6. PubMed ID: 1791266
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial.
    Detke MJ; Lu Y; Goldstein DJ; Hayes JR; Demitrack MA
    J Clin Psychiatry; 2002 Apr; 63(4):308-15. PubMed ID: 12000204
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Evaluation studies on the efficacy of an antidepressant drug].
    Boyer P
    Encephale; 1995 Feb; 21 Spec No 1():27-30. PubMed ID: 7729351
    [No Abstract]   [Full Text] [Related]  

  • 35. Risperidone augmentation decreases rapid eye movement sleep and decreases wake in treatment-resistant depressed patients.
    Sharpley AL; Bhagwagar Z; Hafizi S; Whale WR; Gijsman HJ; Cowen PJ
    J Clin Psychiatry; 2003 Feb; 64(2):192-6. PubMed ID: 12633128
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fluvoxamine maleate in the treatment of depression: a single-center, double-blind, placebo-controlled comparison with imipramine in outpatients.
    Claghorn JL; Earl CQ; Walczak DD; Stoner KA; Wong LF; Kanter D; Houser VP
    J Clin Psychopharmacol; 1996 Apr; 16(2):113-20. PubMed ID: 8690826
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bromocriptine treatment of tricyclic and heterocyclic antidepressant-resistant depression.
    Inoue T; Tsuchiya K; Miura J; Sakakibara S; Denda K; Kasahara T; Koyama T
    Biol Psychiatry; 1996 Jul; 40(2):151-3. PubMed ID: 8793048
    [No Abstract]   [Full Text] [Related]  

  • 38. Efficacy issues with antidepressants.
    Fawcett J; Barkin RL
    J Clin Psychiatry; 1997; 58 Suppl 6():32-9. PubMed ID: 9227671
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Augmentation strategies in patients with refractory depression.
    Nemeroff CB
    Depress Anxiety; 1996-1997; 4(4):169-81. PubMed ID: 9166649
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Which depressed patients respond to nefazodone and when?
    Trivedi MH; Rush AJ; Pan JY; Carmody TJ
    J Clin Psychiatry; 2001 Mar; 62(3):158-63. PubMed ID: 11305700
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.